Article

USFDA declined the approval of Pfizer’s Herceptin biosimilar for breast cancer treatment.
Pfizer’s biosimilar-PF-05280014 has shown equivalence in the objective response rate with Herceptin in HER2-positive metastatic breast cancer patients in clinical studies.

You have read of your 8 free articles this month.

Subscribe to
Medgenera All-Access

Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.

Access articles & resources worth up to US $4, 000 per month.

Register with your email to read the full article.

This article is FREE for you! Unlock the unlimited access by subscribing to Medgenera All-Access.

More in NEWLY PUBLISHED


NEWLY PUBLISHED

Top Companies Leading the Rare Disease Drug Discovery

KEY POINTS Here are the six companies playing on the front foot in the segment of rare diseases drug discovery. ...

NEWLY PUBLISHED

Liquid Biopsy: An Industrial Review

KEY POINTS The liquid biopsy market is forecasted to grow at a CAGR of 20.6 percent to reach over $3 ...

MARKET INSIGHTS

Skin Cancers: The Sunny Challenge of Future (Potential Drugs and Treatments in Development)

KEY POINTS Ozone depletion, greenhouse gas-induced global warming, rising earth temperature is interacting to put a severe effect on human ...

MARKET INSIGHTS

Billion Dollars Healthcare Startups (2018)

KEY POINTS A unicorn is a startup company with a current valuation of US$1 billion or more. Medgenera DATALABS has ...

Most Popular


GROW

7 New Ideas to Start a Healthcare Business in India (2018)

Seven new #healthcare #business ideas in India in 2018. Which one would you prefer to pursue?

NEWLY PUBLISHED

Pharma Patents: Can India Reward Incremental Innovation?

Chandramouli Natarajan is an Associate Scientist, Ricon pharma LLC, Denville, USA. He has presented his opinion and views on the Pharmaceutical patents issues in India. This article is available for free to read and share.

Leave a reply